Skip to main content

Table 1 Demographic, clinical, pathological, and treatment characteristics of the BRAF+ and BRAF− melanoma groups

From: BRAF mutation correlates with worse local–regional control following radiation therapy in patients with stage III melanoma

Variable BRAF+
(n = 53)
BRAF
(n = 52)
P
Age (years)
 ≤ 50 23 (43%) 10 (19%) 0.01
 > 50 30 (57%) 42 (81%)  
Sex
 Male 36 (68%) 34 (65%) 0.89
 Female 17 (32%) 18 (35%)  
Site of primary
 Head and Neck 10 (19%) 23 (43%)  
 Trunk 18 (34%) 6 (11%) 0.02
 Arm 10 (19%) 9 (17%)  
 Leg 11 (21%) 9 (17%)  
 Unknown (found only in LNs) 4 (8%) 5 (9%)  
Site of LND
 Cervical 7 (19%) 14 (44%) 0.09
 Axillary 18 (50%) 11 (34%)  
 Inguinal 11 (31%) 7 (22%)  
Depth of invasion at biopsy
 T1 (≤ 1 mm) 3 (6%) 1 (2%)  
 T2 (> 1–2 mm) 4 (8%) 2 (4%) 0.58
 T3 (> 2–4 mm) 5 (10%) 8 (16%)  
 T4 (> 4 mm) 16 (32%) 13 (27%)  
 Unknown 22 (44%) 25 (51%)  
Ulceration in biopsy
 No 17 (32%) 11 (21%) 0.38
 Yes 19 (36%) 19 (37%)  
 Unknown 17 (32%) 22 (42%)  
# of Mitosis in Biopsy (mm2)
 0–2 10 (19%) 4 (8%) 0.04
 3–5 6 (11%) 11 (21%)  
 > 5 20 (38%) 11 (21%)  
 Unknown 17 (32%) 26 (50%)  
# of LNs positive in LND
 1 (N1) 8 (35%) 8 (42%) 0.86
 2 or 3 (N2) 14 (61%) 10 (53%)  
 4 + (N3) 1 (4%) 1 (5%)  
ECE found in LND
 Yes 20 (56%) 14 (44%) 0.47
 No 16 (44%) 18 (56%)